Results 31 to 40 of about 166,676 (142)

Low expression predicts adverse prognosis in cytogenetically normal acute myeloid leukemia

open access: yesTumor Biology, 2017
Dysregulation of NKD1 has been identified in several solid tumors. However, the status of NKD1 expression and its clinical implication in acute myeloid leukemia remain largely elusive.
Jing-dong Zhou   +10 more
doaj   +1 more source

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

open access: yesHaematologica, 2018
Allogeneic hematopoietic stem cell transplantation is the optimal care for patients with high-risk or intermediate - acute myeloid leukemia. In patients lacking matched sibling donor, haploidentical donors are an option.
Dalila Salvatore   +16 more
doaj   +1 more source

Cutaneous myeloid sarcoma associated with chronic myeloid leukemia [PDF]

open access: yesAnais Brasileiros de Dermatologia, 2017
: Myeloid sarcoma is an extramedullary tumor of malignant myeloid cells often associated with acute myeloid leukemia, chronic myeloproliferative disorders and myelodysplastic syndromes. The skin is one of the most commonly affected sites.
Erica Rodrigues de Araujo Vasconcelos   +2 more
doaj   +1 more source

The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34+CD123+ cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors

open access: yesHaematologica, 2018
Diseases with clonal hematopoiesis such as myelodysplastic syndrome and acute myeloid leukemia have high rates of relapse. Only a small subset of acute myeloid leukemia patients are cured with chemotherapy alone. Relapse in these diseases occurs at least
Rajeswaran Mani   +18 more
doaj   +1 more source

The Topology of Mutated Driver Pathways [PDF]

open access: yesarXiv, 2019
Much progress has been made, and continues to be made, towards identifying candidate mutated driver pathways in cancer. However, no systematic approach to understanding how candidate pathways relate to each other for a given cancer (such as Acute myeloid leukemia), and how one type of cancer may be similar or different from another with regard to their
arxiv  

Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group

open access: yesHaematologica, 2018
Assessment of minimal residual disease has emerged as a powerful prognostic factor in acute myeloid leukemia. In this study, we investigated the potential of IDH1/2 mutations as targets for minimal residual disease assessment in acute myeloid leukemia ...
Yann Ferret   +14 more
doaj   +1 more source

A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1)

open access: yesHaematologica, 2008
Acute myeloid leukemia with mutated NPM1 gene and aberrant cytoplasmic expression of nucleophosmin (NPMc+ acute myeloid leukemia) shows distinctive biological and clinical features.
Arcangelo Liso   +22 more
doaj   +1 more source

Development of pediatric myeloid leukemia may be related to the repeatedbone-remodeling during bone-growth [PDF]

open access: yesarXiv, 2018
Acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) are two major formsof leukemia developed from myeloid cells (MCs). To understand why AML and CML occurin children, we analyzed the causes and the mechanism of cell transformation of a MC. I.
arxiv  

A Study of Age and Sex Bias in Multiple Instance Learning based Classification of Acute Myeloid Leukemia Subtypes [PDF]

open access: yesarXiv, 2023
Accurate classification of Acute Myeloid Leukemia (AML) subtypes is crucial for clinical decision-making and patient care. In this study, we investigate the potential presence of age and sex bias in AML subtype classification using Multiple Instance Learning (MIL) architectures.
arxiv  

De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

open access: yesHaematologica, 2019
Despite the advent of tyrosine kinase inhibitors, a proportion of chronic myeloid leukemia patients in chronic phase fail to respond to imatinib or to second-generation inhibitors and progress to blast crisis. Until now, improvements in the understanding
Vera Magistroni   +27 more
doaj   +1 more source

Home - About - Disclaimer - Privacy